Skip to content
Skip to content

Independent e-magazine

the OUTSPOKEN digest

FDA Approves Nelkarmi for Previously Treated ALK-Positive Lung Cancer, Based on a 49 Percent Response Rate

Neladalkib is cleared for patients who have already tried alectinib or other ALK pills. Response and durability come from a single-arm trial, and the approval is conditional on further data.

Outspoken Digest Health Desk

Thursday, November 19, 2026/2 min read

An illustration of a pair of human lungs with the windpipe and bronchial branches in pink, published by the US National Institutes of Health in 2024, a neutral illustration of the organ and not of the drug, the trial, any tumour or any patient
Photo: Courtesy of NIAID Ryan Kissinger via Wikimedia Commons (Public domain)

The FDA has granted accelerated approval to neladalkib, sold as Nelkarmi, for adults whose ALK-positive non-small cell lung cancer has already outlasted earlier ALK-targeted pills. The agency's own approval notice is dated Tuesday 17 November, ten days ahead of the 27 November target date GSK cited. Memorial Sloan Kettering, whose physician led the trial, published its account on Thursday.

The approval covers two groups, in the unresectable, locally advanced or metastatic setting: patients whose only earlier ALK inhibitor was alectinib, and patients who have had at least two ALK inhibitors plus platinum-based chemotherapy. It does not cover people starting treatment for the first time. A separate phase 3 trial, ALKAZAR, is testing the drug in that earlier setting, according to GSK's press release.

What did the ALKOVE-1 trial show?

The approval rests on ALKOVE-1, a single-arm, open-label, multi-cohort study, the FDA says, with response judged by blinded independent review. Among 67 patients whose only earlier ALK inhibitor was alectinib, 49 percent responded (95 percent confidence interval 37 to 62). Of those who responded, 76 percent kept responding for at least six months and 52 percent for at least twelve.

In the heavily pretreated group of 155 patients, the response rate was 32 percent (confidence interval 24 to 40). Of those responders, 69 percent held on for six months and 51 percent for a year. GSK adds that cancer in the brain shrank in 11 of 20 patients in the alectinib group and 14 of 53 in the heavily pretreated group.

There was no comparison arm, so the trial cannot say whether people live longer than they would on another drug. That is what an accelerated approval means: the benefit is judged on a surrogate, here tumour response and its durability, and the company must confirm it later.

What are the side effects and the dose?

The FDA lists warnings for liver, kidney and eye toxicity, raised creatine phosphokinase and harm to an unborn baby. The most common adverse reactions, at 20 percent or more, were liver effects, musculoskeletal pain, constipation, altered taste, nerve symptoms, swelling and fatigue. GSK says 5 percent of patients stopped the drug permanently because of side effects, most often liver problems. The recommended dose is 150 mg by mouth once daily, until the disease progresses or toxicity becomes unacceptable.

Who developed it and what happens next?

The FDA names Nuvalent as the applicant, and GSK describes the drug as part of the portfolio from its recent acquisition of that company. Memorial Sloan Kettering reports that Dr Alexander Drilon led the drug's development and the trial, and that he is a paid Nuvalent consultant and advisory board member. GSK's chief scientific officer called it the company's second new lung cancer medicine approved this year. The release describes approval in the United States only and gives no launch date or price.

This article is reporting, not medical advice. Treatment decisions for lung cancer, including whether a targeted drug is suitable, belong with an oncologist who knows the patient's tumour profile and history.

The next test is whether the response durability seen so far holds in longer follow-up and in the first-line trial, since an accelerated approval stays conditional until the confirmatory data are in.

Published in The Outspoken Digest

Editorial desk

Outspoken Digest Health Desk

Medicine, public health and the research behind the headlines, read carefully.

Newsletter

The Digest, in your inbox

One edition, sent when it is ready. No noise, and your address is never passed on.

We send a confirmation first. One click to leave, always.

Share this story

the OUTSPOKEN digest

Beyond boundaries. Independent stories on technology, culture, and the trends shaping how we live.